Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Investing Activities (2016 - 2026)

Cytosorbents filings provide 15 years of Cash from Investing Activities readings, the most recent being -$291000.0 for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 134.68% to -$291000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$415000.0, a 37.97% increase, with the full-year FY2025 number at -$415000.0, up 37.97% from a year prior.
  • Cash from Investing Activities hit -$291000.0 in Q4 2025 for Cytosorbents, down from $55000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $140285.0 in Q2 2023 to a low of -$4.7 million in Q2 2022.
  • Median Cash from Investing Activities over the past 5 years was -$274357.5 (2023), compared with a mean of -$637853.6.
  • Biggest five-year swings in Cash from Investing Activities: tumbled 528.53% in 2021 and later soared 118.39% in 2025.
  • Cytosorbents' Cash from Investing Activities stood at -$1.7 million in 2021, then surged by 87.68% to -$206080.0 in 2022, then skyrocketed by 34.04% to -$135922.0 in 2023, then grew by 8.77% to -$124000.0 in 2024, then tumbled by 134.68% to -$291000.0 in 2025.
  • The last three reported values for Cash from Investing Activities were -$291000.0 (Q4 2025), $55000.0 (Q3 2025), and -$131758.0 (Q2 2025) per Business Quant data.